Lutetium-177 PSMA Therapy for Prostate Cancer in Germany

Lutetium-177 (Lu-177) PSMA therapy is a targeted radiation treatment for stage 4 prostate cancer that has spread to other parts of the body and keeps progressing despite earlier treatment. It pairs a radioactive form of the element lutetium with a molecule that attaches to PSMA, a protein found on the surface of most prostate cancer cells, so the radiation is delivered directly to the cancer cells.

For patients considering care in Germany, Treatment in Germany (TIG) can review medical records and help international patients arrange specialist assessment for this treatment. The German treating team decides whether it is suitable.

Lu-177 PSMA Mechanism in Prostate Cancer

PSMA is a protein on the surface of prostate cancer cells, often at much higher levels than in normal tissue.

The treatment works in four steps [1]:

• The radioligand pairs a PSMA-binding molecule (vipivotide tetraxetan) with lutetium-177.
• After intravenous injection, it travels through the bloodstream and attaches to PSMA-expressing cells; the bound complex can then be internalised by the cell.
• Lutetium-177 emits beta radiation that can damage DNA in the targeted cell and nearby cells.
• The beta radiation travels a short distance in tissue, about 0.67 mm on average and up to 2 mm at most.

Because the drug circulates through the body, it can reach PSMA-expressing prostate cancer in bone, lymph nodes and soft tissue at the same time. Pluvicto is the marketed name, and research papers call the same compound 177Lu-PSMA-617. Taxane chemotherapy for prostate cancer, such as docetaxel, disrupts the internal scaffolding (microtubules) that dividing cells need, and it does not depend on a tumour marker. By contrast, lutetium-177 PSMA radioligand therapy relies on PSMA binding to deliver radiation to target-expressing disease, making PSMA expression and its distribution across lesions important considerations in patient selection.

Lu-177 PSMA Eligibility for Prostate Cancer

Castration-resistant means the cancer keeps growing even though hormone therapy for prostate cancer has lowered testosterone. Eligibility follows the EU authorisation above and the factors below, assessed together by the treating team.

The 2026 update by the authors of the German S3 guideline describes this authorised setting and also notes a possible first-line role in mCRPC for patients who previously received darolutamide plus ADT and docetaxel in the hormone-sensitive stage. The approval rests on the VISION trial, which randomly assigned 831 patients who had received at least one androgen receptor pathway inhibitor and one or two taxane regimens [1] [2] [3].

The table above summarises what the team checks before treatment.

Rising PSA levels can indicate biochemical progression, but PSA alone does not determine suitability; imaging, previous treatment, laboratory results and general health also matter, and the treating team makes the final decision. In 2026, an application to extend the EU indication to patients after an androgen receptor pathway inhibitor for whom chemotherapy is not yet clinically indicated was withdrawn [4].

Patients who are not suitable for Lu-177 PSMA therapy may have other treatment options for prostate cancer, depending on previous treatment, symptoms, molecular findings and overall health. The treating team or tumour board can assess these alternatives.

PSMA PET Imaging Before Lu-177 PSMA Therapy

PSMA PET/CT shows where the prostate cancer is and whether it takes up the PSMA tracer. In VISION, gallium-68 PSMA-11 PET was used, and patients needed at least one lesion with uptake above normal liver [1] [3].

What matters is the pattern across the whole body, not whether a single lesion lights up. Three findings change how a scan is read [5]:

• Low uptake: a lesion with low PSMA uptake may receive less radiation, and lower tumour uptake has been associated with a lower likelihood of response.
• Discordant disease: lesions that are active on fluorodeoxyglucose (FDG) PET but PSMA-negative are a recognised predictor of poor response, so FDG PET may be added in selected patients.
• Mixed findings: when some lesions take up the PSMA tracer, and others do not, benefit may differ between sites.

PSMA PET supports treatment selection in prostate cancer, but a positive scan does not by itself guarantee eligibility or response. If you are unsure whether your PSMA PET and treatment history fit, a specialist review of your records before you plan travel can help; the German specialists decide on eligibility.

Lu-177 PSMA Treatment Process and Monitoring

Before the first dose, the nuclear medicine and oncology team reviews the PSMA PET, previous treatments, and baseline blood counts, kidney function, and liver function. The EU regimen is 7,400 MBq (7.4 GBq) by intravenous injection every 6 weeks (plus or minus one week) for up to 6 doses, which means a full course spans about 30 weeks. Treatment stops earlier if the prostate cancer progresses or toxicity becomes unacceptable. Restarting after a break or continuing beyond six doses is not part of this routine regimen and should be considered only in an appropriate specialist or research context, taking account of the limited and evolving evidence [1] [6].

Between doses, blood counts, kidney function and liver function are checked again. The dose can be reduced, delayed or stopped according to the results, and a delay of more than 4 weeks caused by an adverse reaction means treatment ends. Patients are advised to drink extra fluids and empty the bladder often to lower bladder radiation exposure.

After each dose, the treating centre gives written radiation-protection instructions. The EU patient leaflet lists general recommendations such as the following [1]:

• Limiting close contact (under 1 metre) with others for 2 days, and with children or pregnant women for 7 days.
• Sleeping apart from others for 3 days, from children for 7 days and from pregnant women for 15 days.
• Avoiding sexual activity for 7 days, and using a condom during treatment and for 14 weeks after the last dose.

Radiation to the testes can affect male fertility, and sperm storage can be discussed before treatment starts.

Lu-177 PSMA Side Effects and Safety in Prostate Cancer

In VISION, the most frequent adverse reactions in men with prostate cancer given Pluvicto plus standard care were fatigue, dry mouth, nausea and anaemia. Adverse events of grade 3 or higher (severe or worse) occurred in 52.7 per cent of patients on Pluvicto plus standard care and 38.0 per cent on standard care alone. Myelosuppression (reduced blood cell production in the bone marrow), including fatal cases, occurred more often with Pluvicto than with standard care alone [1] [3].

The chart above shows how often selected reactions occurred and how many cases were severe (grade 3 to 4). Most cases of fatigue, dry mouth and nausea were mild to moderate, while grade 3 to 4 anaemia occurred in 12.9 per cent of patients and grade 3 to 4 fatigue in 6.6 per cent. Falling blood counts and declining kidney function matter most for safety, because depending on severity they can require a dose delay, a dose reduction or permanent discontinuation.

The medicine also collects in the salivary glands and kidneys, which is why dry mouth and kidney function are monitored. Patients with reduced kidney function need closer attention, and extensive previous chemotherapy or long-lasting blood count problems may reduce bone marrow reserve and call for extra caution [1][3] [5].

The table above shows what is checked during treatment and how the dose is adjusted if results are abnormal. The dose can be reduced by 20% only once and is not increased again. Treatment also adds to lifetime radiation exposure, which the product information links to a higher long-term cancer risk [1].

Patients should contact their treating team promptly for fever or other signs of infection, unusual bleeding or bruising, severe vomiting or diarrhoea, much less urine than usual, or new back pain with leg weakness or numbness.

Monitoring Prostate Cancer After Lu-177 PSMA Therapy

Response to treatment for prostate cancer is judged from several measures together:

• PSA trend.
• Symptoms and clinical status, including pain.
• Blood tests.
• Imaging when clinically indicated.
• Treatment tolerance.
• Changes in known disease.

PSA is useful but imperfect. Early PSA changes have been studied as a possible sign of response, but PSA alone cannot show whether treatment is working, so the team weighs it with the measures above [7].

Accessing Lu-177 PSMA Treatment in Germany

In Germany, a specialist assessment of the prostate cancer is needed first and typically covers PSMA imaging, previous therapies and laboratory results, often with input from oncology and urology colleagues.

Where Can International Patients Get Lu-177 PSMA Therapy in Germany?

Patients can be assessed at German specialist nuclear medicine or theranostic centres that provide Lu-177 PSMA treatment for prostate cancer. Depending on radiation protection requirements and local practice, treatment may involve an inpatient stay after each administration, and arrangements can vary between centres.

To prepare for specialist review of prostate cancer treatment, international patients need the following:

• Recent pathology report.
• Recent imaging, including PSMA PET.
• Treatment history.
• Recent laboratory results.

Questions to ask about prostate cancer treatment:

• Does my PSMA PET meet the criteria?
• Which results could delay doses?
• Will I need a hospital stay?

Total costs of prostate cancer treatment depend on the number of doses, any inpatient days, imaging, laboratory monitoring, and the treating centre. International patients can ask the German centre for a written cost estimate before travelling.

TIG GmbH (Treatment in Germany) can review a patient's prostate cancer records, previous treatment and PSMA imaging to help patients understand whether a specialist Lu-177 PSMA assessment in Germany may be appropriate. TIG can connect patients with German nuclear medicine or oncology specialists who treat prostate cancer and coordinate consultation and treatment-planning steps. The German medical team determines eligibility and treatment. Patients who would like their records reviewed can contact TIG through and ask which documents to send first.

References

1. European Medicines Agency. Pluvicto (lutetium (177Lu) vipivotide tetraxetan): Product Information.

2. Grimm MO, Gratzke C, Hadaschik B, et al. Aktualisierung S3-Leitlinie zum metastasierten Prostatakarzinom: Leitlinienempfehlungen und Expertenkonsens. Urologie. 2026;65(5). doi:10.1007/s00120-026-02817-4 (in German).

3. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (VISION). N Engl J Med. 2021;385(12):1091-1103.

4. European Medicines Agency. Pluvicto: withdrawal of application for variation to the marketing authorisation.

5. Kratochwil C, et al. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50:2830-2845.

6. Mirshahvalad SA, Iravani A, Fendler WP, et al. Rechallenge and Extended 177Lu-PSMA Therapy in Metastatic Prostate Cancer. J Nucl Med. 2026;67(1):4-11.

7. Gafita A, Heck MM, Rauscher I, et al. Early Prostate-Specific Antigen Changes and Clinical Outcome After 177Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2020;61(10):1476-1483.

Why Patients Worldwide Prefer Our Medical Services in Germany – Key Benefits Explained

International patients planning prostate cancer treatment in Germany may need support with hospital consultations, medical documentation, translations, and travel arrangements. TIG GmbH helps coordinate these practical steps and communication with healthcare providers according to each patient's needs and the services agreed.

The table above compares the support and coordination services offered through TIG GmbH with the arrangements patients may need to manage when booking directly with a clinic.